Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 7/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 3/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089146 | 0.91 | CMKLR1 (0.37) | SCN9ACMKLR1PTGDR2PDE9AKDM5A | |
| SCHEMBL4094452 | 0.91 | CMKLR1 (0.37) | SCN9ACMKLR1PTGDR2PDE9ARXRA | |
| SCHEMBL4183229 | 0.86 | CMKLR1 (0.36) | CMKLR1PTGDR2PDE9ARXRARXRB | |
| SCHEMBL4088673 | 0.83 | CMKLR1 (0.37) | CMKLR1PTGDR2RXRARXRBRXRG | |
| SCHEMBL5381479 | 0.82 | CMKLR1 (0.34) | CMKLR1PTGDR2PDE9AFLT3SYK | |
| SCHEMBL4094652 | 0.82 | RAB9A (0.37) | CMKLR1KDM1ARXRARXRBRXRG | |
| SCHEMBL4089935 | 0.81 | CMKLR1 (0.40) | CMKLR1PTGDR2RXRARXRBRXRG | |
| SCHEMBL4080211 | 0.81 | SLC6A2 (0.36) | CMKLR1KDM1AHRH3 | |
| SCHEMBL4079783 | 0.80 | CMKLR1 (0.36) | CMKLR1KDM1ARXRARXRBRXRG | |
| SCHEMBL4082983 | 0.78 | SLC6A2 (0.38) | CMKLR1KDM1ARXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | SCN9A 2691/4885CMKLR1 1073/4885KDM1A 3862/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | SCN9A 2716/4885CMKLR1 1136/4885KDM1A 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.